CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers. The company's lead product candidate is CTM-N2D, which consists of expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, which utilizes iPSC as a starting material to generate gdNKT, a synthetic hybrid of a gamma delta T cell and a NK cell; and CTM-GDT, a product candidate that consists of expanded gamma delta T cells, and exploits the multiple recognition system of gamma delta T cell to recognize and treat a range of cancers. The company was incorporated in 2018 and is headquartered in Singapore.
Earnings for CytoMed Therapeutics Limited (GDTC)
Earnings in 2023 (TTM): $-3,131,501
According to CytoMed Therapeutics Limited's latest financial reports the company's current earnings (TTM) are $-3,131,501. The earnings displayed on this page is the company's Pretax Income.
Earnings history of CytoMed Therapeutics Limited
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-3,131,501 | $-3,131,788 |
| 2022 | $-3,129,812 | $-3,227,956 |
| 2021 | $-2,074,531 | $-2,074,531 |
| 2020 | $-1,942,242 | $-1,942,242 |
| 2019 | $-632,611 | $-632,611 |